Although long-acting bronchodilators are not approved to treat acute respiratory failure (ARF), the older adult in this case clinically improved after three doses of revefenacin and arformoterol.

Additional studies are necessary to determine the efficacy and safety of long-acting bronchodilators to treat acute respiratory distress syndrome (ARDS) or acute exacerbations of chronic lung conditions.

Further analysis on the incidence of adverse events, particularly for patients in the ICU, is also warranted.

This report describes the case of a 79-year-old man admitted to the intensive care unit (ICU) for acute hypoxemic respiratory failure due to coronavirus disease 2019 (COVID-19) and treated with long-acting nebulized bronchodilators, arformoterol and revefenacin.

Read More